• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: AD

Vitamin B in MCI: VITACOG results

February 8, 2012  

Future look: novel AD therapies in phase III testing

January 25, 2012  

ADAPT trial update: NSAIDs in AD

December 14, 2011  

No effect of cholesterol reduction on AD measures

November 9, 2011  

BP and Alzheimer’s disease: results inconclusive

September 21, 2011  

Beta-amyloid accumulation prior to cognitive impairment: longitudinal data

August 24, 2011  

AD progression associated with elevated coated platelet level

August 3, 2011  

Anxiety associated with cortical atrophy in AD

July 6, 2011  

Traumatic brain injury: no effect on AD phenotype

July 6, 2011  

Plasma clusterin a possible biomarker of AD severity

June 29, 2011  
Previous
3
4
5
6
7
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
  • Ultomiris (ravulizumab) now publicly reimbursed in gMG posted on April 7, 2026
  • Ofatumumab – new data on efficacy and safety posted on April 14, 2025
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions